An anonymous reader shared this report from USA Today: He's the founder of Telegram. He was arrested in France. He also claims to have fathered at least 100 children...

The 39-year-old Russian-born billionaire often keeps his personal life out of the spotlight. Something he has shared, however, is that, despite never marrying and preferring to live alone, he's fathered at least 100 children through anonymous sperm donation... Durov noted he plans to "open-source" his DNA so his biological children can find each other more easily. "I also want to help destigmatize the whole notion of sperm donation and incentivize more healthy men to do it, so that families struggling to have kids can enjoy more options," he wrote. "Defy convention — redefine the norm...!"
"Sperm donation has allowed many people to have families who otherwise wouldn't be able to," the article points out. But it also adds that the anonymous practice "has drawn several detractors, including from those who've been conceived through it." These people have shared with USA TODAY the mental turmoil of learning they have, in some cases, hundreds of half-siblings... One of the main criticisms of the practice is that the anonymity of the donor makes it difficult or impossible for donor-conceived people to learn about their health and treat genetically inherited medical issues. Even when donor-conceived people have their donor's identity and contact information, there's still no guarantee they'll respond or tell the truth. Also, most sperm banks in the United States aren't legally required to keep records of siblings or cap the number of families that can use a specific donor. As a result, donor-conceived people with many siblings often live in fear of accidentally having children with one of their half-siblings, or even having children with their own father if they were to pursue donor insemination.

An anonymous Slashdot reader shared this report from NBC News: A new approach to a routine blood test could predict a person's 30-year risk of heart disease, research published Saturday in the New England Journal of Medicine found.

Doctors have long assessed their patients' risk for cardiovascular disease by using a blood test to look at cholesterol levels, focusing particularly on LDL or "bad" cholesterol. But limiting blood testing to just cholesterol misses important — and usually silent — risk factors, experts say... Lead study author Dr. Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital in Boston and his team found that in addition to LDL cholesterol, two other markers — a type of fat in the blood called lipoprotein (a), or Lp(a), and an indicator of inflammation — are important predictors of a person's risk of heart attack, stroke and coronary heart disease...

In the study, the researchers analyzed data from nearly 30,000 U.S. women who were part of the Women's Health Study. On average, the women were 55 years old when they enrolled in the years 1992 through 1995. About 13% — roughly 3,600 participants — had either a heart attack or stroke, had surgery to fix a narrowed or blocked artery, or died from heart disease over the 30-year follow-up period... All of the women had blood tests done at the beginning of the study to measure their LDL cholesterol, Lp(a) and C-reactive protein levels, a marker of inflammation in the body. These measurements, individually as well as together, appeared to predict a woman's heart health over the next three decades, the study found.

Women with the highest levels of LDL cholesterol had a 36% higher risk for heart disease compared with those with the lowest levels. The highest levels of Lp(a) indicated a 33% elevated risk, and those with the highest levels of CRP were 70% more at risk for heart disease. When the three were looked at together, women who had the highest levels were 1.5 times more likely to have a stroke and over three times more likely to develop coronary heart disease over the next 30 years compared with women with the lowest levels.

All of the markers have been individually linked to higher risk of heart disease, but "all three represent different biological processes. They tell us why someone is actually at risk," Ridker said.

One of Slashdot's most-visited stories of all time was the 2016 story asking: Can Cow Backpacks Reduce Global Methane Emissions? "Enteric fermentation," or livestock's digestive process, accounts for 22 percent of all U.S. methane emissions, and the manure they produce makes up eight percent more, according to the U.S. Environmental Protection Agency... Methane, like carbon, is a greenhouse gas, but methane's global warming impact per molecule is 25 times greater than carbon's, according to the EPA.
Cow methane still "heats the Earth more than every flight across the world combined," the Washington Post added today, reporting on a new $30 million genetic engineering experiment undertaken by the Innovative Genomics Institute and the University of California at Davis.

Its mission: to transform a cow's gut so it no longer releases methane. Using tools that snip and transfer DNA, researchers plan to genetically engineer microbes in the cow stomach to eliminate those emissions. If they succeed, they could wipe out the world's largest human-made source of methane and help change the trajectory of planetary warming... The average cow produces around 220 pounds of methane per year, or around half the emissions of an average car; cows are currently responsible for around 4 percent of global warming, according to the Food and Agriculture Organization...

Scientists envision a kind of probiotic pill, given to the cow at birth, that can transform its microbiome permanently...

The current project doesn't target only a particular cow species — it takes aim at the microbiome itself, offering a solution that could apply to all of them. Brad Ringeisen, executive director at the genomics institute, cut his teeth running biotechnology at the U.S. defense research agency DARPA, which helped pioneer transformative innovations including the internet, miniaturized GPS, stealth aircraft and the computer mouse. "I'm taking the DARPA mentality here," he said. "Let's solve it for all cows, not just a fraction of the cows." ...]

"There's no reason a cow has to produce methane," Ringeisen said. So what if scientists could just ... turn it off?
"I personally think this is the one that can make the biggest impact in the world," Ringeisen said. "Say you could wave a magic wand and eliminate all those emissions."

The article says that currently the scientists are feeding red-seaweed oil to a cow to measure the changes, to prepare for their final goal: "replicate those changes with gene editing." (They're using machine learning to reassemble the hundreds of pieces of each miccroorganism's DNA, so they can understand which changes they need to make with their early-intervention probiotic.) Such a probiotic could also improve a farm's productivity. Cows can lose up to 12 percent of their energy through burping up methane; other ruminants, like sheep and goats, also lose energy in this way. "If there is a way to redirect that hydrogen and convert it into milk, meat, wool — it would be much more accepted by farmers," said Ermias Kebreab [a professor of animal science at UC-Davis].

Early treatments will be tested on the cows at Davis, with researchers tracking their burps to evaluate the drop-off in methane emissions. There is still a long way to go. While scientists have proved that they can gene-edit microbes, researchers have so far only shown that they can edit a small fraction of the microbes in the cow gut — or the human gut, for that matter. Institute researchers are developing microbial gene-editing tools, even as they are mapping the species of the microbiome. They are building the plane while flying it.

The teams have received enough funding for seven years of research. The project started last year, and they hope to have a trial treatment ready for testing in cows in the next two years.

In a blog post on Wednesday, Neuralink said its second human recipient is using the brain chip to play Counter-Strike 2 and develop 3D designs in CAD software. "Alex" was given the brain chip last month to help restore his autonomy after a spinal cord injury. PCMag reports: Like the first Neuralink patient, Noland Arbaugh, Alex has also been using the brain chip to play his favorite computer games, such as Counter-Strike 2. Before, Alex had to use a mouth-operated controller, called a QuadStick, to play the first-person shooter. But even then, the controller limited him to only moving or aiming his weapon at a single time, never simultaneously like a normal Counter-Strike player. In other words, Alex had to essentially switch back and forth between the mouse and keyboard functions while playing the game. But thanks to Neuralink, he can now aim with the implant, and simultaneously move while using the QuadStick. [...]

In the blog post, Neuralink also addressed a problem the company faced when placing the chip in Arbaugh, the first patient. Despite a successful surgery, about 85% of the thread-based electrodes attached to his brain later became displaced, undermining the full potential of the chip to read neural signals. Although Arbaugh can still use his implant effectively, Neuralink wanted to avoid a repeat with Alex. In response, the company developed several "mitigations," which include reducing the chance of an air pocket forming during surgery and placing the implant deeper into the brain tissue. "Promisingly, we have observed no thread retraction in our second participant," the company said of Alex.

Whether Alex's implant outperforms the brain chip in Arbaugh was left unclear. In the meantime, Neuralink says it's working on ways to enhance the controls on the technology "to deliver full mouse and video game controller functionality." "Additionally, we plan to enable the Link [brain chip] to interact with the physical world, allowing users to feed themselves and move more independently by controlling a robotic arm or their wheelchair," the company said. You can watch Alex playing Counter-Strike 2 on YouTube.

An anonymous reader quotes a report from Wired: Florida's ban on cultivated meat is being challenged in federal court in a lawsuit that was filed yesterday. The case is being brought by the cultivated meat firm Upside Foods and the Institute of Justice (IJ), a nonprofit public interest law firm. Florida governor Ron DeSantis signed the legislation making the sale of cultivated meat illegal in Florida on May 1, and the bill came into effect on July 1. Alabama passed a similar bill banning cultivated meat that will come into effect from October 1. The case brought by Upside Foods and the IJ argues that Florida's ban is unconstitutional in three different ways. First, they argue, the ban violates theSupremacy Clause that gives federal law priority over state law in certain instances. The court case argues that the Florida ban violates two different provisions in the Federal Meat Inspection Act and Poultry Products Inspection Act.

The legal complaint (PDF) also alleges that the ban violates theCommerce Clause, which gives the US Congress exclusive power to regulate interstate commerce. The IJ argues that the Commerce Clause restricts states from enacting laws that unduly restrict interstate commerce, and that Florida's ban in its current form has the effect of discriminating against it. "Florida's law has nothing to do with protecting health and safety," said IJ senior attorney Paul Sherman in a press conference today. "It is a transparent example of economic protectionism." Sherman said that Upside Foods and the IJ would also apply for a preliminary injunction that would allow the company to sell cultivated meat in Florida while the legal challenge is still ongoing. The complaint says that Upside had planned to distribute its cultivated chicken at Art Basel in Miami in early December 2024. The company protested the Florida ban by holding a tasting of its chicken on June 27 in Miami, shortly before the ban came into effect. Sherman said that the Alabama ban was also "in our sights" but that the IJ had targeted the Florida law as it came into effect before the Alabama ban. "We're hoping we'll be able to get a quick ruling [in Florida] on a preliminary injunction there," and use that as a precedent to challenge the Alabama ban, he said. "Consumers should decide what kind of meat they want to buy and feed their families -- not politicians," said the Good Food Institute (GFI), a nonprofit focused on advancing alternative proteins and which is serving as a consulting consul in this case. "This lawsuit seeks to protect these consumer rights, along with the rights of companies to compete in a fair and open marketplace."

The Wall Street Journal visits scientists at Harvard University's Wyss Institute for Biologically Inspired Engineering who are researching a "sugar-to-fiber" enzyme (normally used by plants to create stalks). They're testing a version they've "encased in spherical nanoparticles — tiny mesh-like cages made of pectin that allow the enzyme to be added to food without being activated until it reaches the intestine.

"Once there, a change in pH causes the cage to expand, freeing the enzyme to float through its holes and start converting sugar to fiber." The Wyss Institute's goal for its enzyme product was to reduce the sugar absorbed from food by 30%, though it has the potential to remove even more than that, says Sam Inverso, director of business development partnerships at the Wyss Institute. The enzyme's ability to turn sugar into fiber is also key, as most Americans don't get nearly enough fiber in their diet, says Adama Sesay, a senior engineer at the Wyss Institute who worked on the project...

The Wyss Institute is now licensing the technology to a company to help bring its enzyme product to market, a process that entails additional testing and work to secure regulatory approval. Inverso says that the aim is for the product to be available to U.S. food manufacturers within the next two years, and that other encapsulated enzymes could follow: products that reduce lactose absorption after drinking milk, or cut gluten after eating bread. For now the enzyme works better in solid food than in a liquid. Producing it in large quantities and at low cost is still a ways off — currently it's 100 times more expensive than raw sugar, Inverso says.
And the Journal notes they're not the only ones working on the problem: San Francisco-based startup Biolumen recently launched a product called Monch Monch, a drink mix made of fibrous, microscopic sponges designed to soak up sugar and prevent it from reaching the bloodstream. At mealtime consumers can blend a teaspoon of Monch Monch, which has no taste, smell or color, into drinks from water to wine. Once it has reached the stomach, the sponges start to swell and sequester sugar, reducing its burden on the body, says Dr. Robert Lustig, Biolumen's co-founder and chief medical officer... One gram of Monch Monch can sequester six grams of sugar, says Lustig... The product, introduced as a dietary supplement, can also be used as a food ingredient under a Food and Drug Administration principle known as "generally recognized as safe." Packets of Monch Monch are available for purchase online, and Biolumen says it is in talks with U.S. food manufacturers it declined to name about its use in other products...

Food companies are betting on other solutions for now. Cereal startup Magic Spoon uses allulose, a natural sugar found in figs and raisins that is growing in popularity, helped by FDA guidance that allows it to be excluded from sugar or added-sugar totals on nutrition labels. Ingredient company Tate & Lyle, which makes allulose from corn kernels, says the sweetener tastes like sugar and adds bulk and caramel color, but passes through the body without being metabolized... Chicago-based Blommer Chocolate recently launched a line of reduced-sugar chocolate and confectionery products made with Incredo, a sugar that has been physically altered to taste sweeter using a mineral carrier that dissolves faster in saliva and targets the sweet-taste receptors on the tongue. Incredo's use enables manufacturers to use up to 50% less sugar, the company says.
The article even notes that "researchers still working to reduce sugar are peddling new technologies, like individual sugar crystals modified to dissolve more quickly in the mouth, making food taste sweeter."

Late Friday Elon Musk appeared on Lex Fridman's podcast for a special eight-hour episode about Neuralink.

It's already been viewed 1,702,036 times on YouTube — and resulted in this report from Reuters: Neuralink has successfully implanted in a second patient its device designed to give paralyzed patients the ability to use digital devices by thinking alone, according to the startup's owner Elon Musk... [Musk] gave few details about the second participant beyond saying the person had a spinal cord injury similar to the first patient, who was paralyzed in a diving accident.

Musk said 400 of the implant's electrodes on the second patient's brain are working. Neuralink on its website states that its implant uses 1,024 electrodes... Musk said he expects Neuralink to provide the implants to eight more patients this year as part of its clinical trials.
Neuralink's device "has allowed the first patient to play video games, browse the internet, post on social media and move a cursor on his laptop," according to the article: The first patient, Noland Arbaugh, was also interviewed on the podcast, along with three Neuralink executives, who gave details about how the implant and the robot-led surgery work. Before Arbaugh received his implant in January, he used a computer by employing a stick in his mouth to tap the screen of a tablet device. Arbaugh said with the implant he now can merely think about what he wants to happen on the computer screen, and the device makes it happen... Arbaugh has improved on his previous world record for the speed at which he can control a cursor with thoughts alone "with only roughly 10, 15% of the electrodes working," Musk said on the podcast.
Fridman said his interview with Musk was "the longest podcast I've ever done," calling their conversation "fascinating, super technical, and wide-ranging... I loved every minute of it."

A new type of antibiotic "targets bacteria in two ways," writes SciTechDaily, which "could make it 100 million times harder for bacteria to develop resistance, according to recent research from the University of Illinois Chicago." Their experiments demonstrate that [a class of synthetic drugs called] macrolones can work two different ways — either by interfering with protein production or corrupting DNA structure. Because bacteria would need to implement defenses to both attacks simultaneously, the researchers calculated that drug resistance is nearly impossible. "The beauty of this antibiotic is that it kills through two different targets in bacteria," said Alexander Mankin, distinguished professor of pharmaceutical sciences at UIC. "If the antibiotic hits both targets at the same concentration, then the bacteria lose their ability to become resistant via the acquisition of random mutations in any of the two targets."

Macrolones are synthetic antibiotics that combine the structures of two widely used antibiotics with different mechanisms. Macrolides, such as erythromycin, block the ribosome, the protein manufacturing factories of the cell. Fluoroquinolones, such as ciprofloxacin, target a bacteria-specific enzyme called DNA gyrase.... "The main outcome from all of this work is the understanding of how we need to go forward," Mankin said. "And the understanding that we're giving to chemists is that you need to optimize these macrolones to hit both targets."
Thanks to long-time Slashdot reader schwit1 for sharing the news.

CNET visits a leading-edge company making an implantable brain-computer-interface that's "experimenting with ChatGPT integration..." We previously covered Synchron's unique approach to implanting its brain-computer-interface (BCI) without the need for open brain surgery. Now the company has integrated OpenAI's ChatGPT into its software, something it says is a world's first for a BCI company...

Typing out messages word by word with the help of a BCI is still time consuming. The addition of AI is seen as a way to make communication faster and easier by taking in the relevant context, like what was last said in a conversation, and anticipating answers a person might want to respond with, providing them with a menu of possible options. Now, instead of typing out each word, answers can be filled in with a single "click." There's a refresh button in case none of the AI answers are right... [ALS patient Mark, one of 10 people in the world testing Synchron's brain implant in a clinical trial] has noticed the AI getting better at providing answers that are more in line with things he might say. "Every once in a while it'll drop an f-bomb, which I tend to do occasionally," he says with a laugh.

Synchron CEO Tom Oxley tells me the company has been experimenting with different AI models for about a year, but the release of OpenAI's ChatGPT-4o in May raised some interesting new possibilities. The "o" in ChatGPT-4o stands for "omni," representative of the fact that this latest version is capable of taking in text, audio and visual inputs all at once to inform its outputs... Oxley envisions the future of BCIs as... having large language models like ChatGPT take in relevant context in the form of text, audio and visuals to provide relevant prompts that users can select with their BCI... Synchron's BCI is expected to cost between $50,000 and $100,000, comparable with the cost of other implanted medical devices like cardiac pacemakers or cochlear implants.
CNET has also released a video — titled "What It's Like Using a Brain Implant With ChatGPT."

Scientists at the University of Texas at Austin have developed a "smart soil" that can keep plants better hydrated and provide a controlled release of nutrients. As reported by New Atlas, tests found that it "drastically improved crop growth while using far less water." From the report: The soil gets its "smart" moniker thanks to the addition of a specially formulated hydrogel, which works to absorb more water vapor from the air overnight, then releasing it to the plants' roots during the day. Incorporating calcium chloride into the hydrogel also provides a slow release of this vital nutrient. The team tested the new smart soil in lab experiments, growing plants in 10 grams of soil, with some including 0.1 g of hydrogel. A day/night cycle was simulated, with 12 hours of darkness at 25 C (77 F) and either 60% or 90% relative humidity, followed by 12 hours of simulated sunlight at 35 C (95 F) and 30% humidity.

Sure enough, plants growing in the hydrogel soil showed a 138% boost to their stem length, compared to the control group. Importantly, the hydrogel-grown plants achieved this even while requiring 40% less direct watering. In future work, the team plans to try incorporating other types of fertilizers, and conducting longer field experiments. The research was published in the journal ACS Materials Letters.

A Californian startup funded by Bill Gates is making rich, fatty "butter" using just carbon dioxide and hydrogen, with other dairy-free alternatives in the works. New Atlas reports: The San Jose company, Savor, uses a thermochemical process to create its animal-like fat, which is free of the environmental footprint of both the dairy industry and plant-based alternatives. "They started with the fact that all fats are made of varying chains of carbon and hydrogen atoms," Gates wrote in a blog post. "Then they set out to make those same carbon and hydrogen chains -- without involving animals or plants. They ultimately developed a process that involves taking carbon dioxide from the air and hydrogen from water, heating them up, and oxidizing them to trigger the separation of fatty acids and then the formulation of fat."

"The idea of switching to lab-made fats and oils may seem strange at first," Gates wrote. "But their potential to significantly reduce our carbon footprint is immense. By harnessing proven technologies and processes, we get one step closer to achieving our climate goals." Savor's 'butter' is easily produced and scalable, but convincing people to swap out butter and other dairy products for 'experimental' foods will remain a challenge for the foreseeable future. Gates is hoping, however, that his support will do more than start a conversation. "The process doesn't release any greenhouse gases, and it uses no farmland and less than a thousandth of the water that traditional agriculture does," he added. "And most important, it tastes really good -- like the real thing, because chemically it is." The research has been published in the journal Nature Sustainability.

The Roddenberry Foundation — named for Star Trek creator Gene Roddenberry — "announced Tuesday that this year's biennial award would focus on artificial intelligence that benefits humanity," reports the Los Angeles Times: Lior Ipp, chief executive of the foundation, told The Times there's a growing recognition that AI is becoming more ubiquitous and will affect all aspects of our lives. "We are trying to ... catalyze folks to think about what AI looks like if it's used for good," Ipp said, "and what it means to use AI responsibly, ethically and toward solving some of the thorny global challenges that exist in the world...."

Ipp said the foundation shares the broad concern about AI and sees the award as a means to potentially contribute to creating those guardrails... Inspiration for the theme was also borne out of the applications the foundation received last time around. Ipp said the prize, which is "issue-agnostic" but focused on early-stage tech, produced compelling uses of AI and machine learning in agriculture, healthcare, biotech and education. "So," he said, "we sort of decided to double down this year on specifically AI and machine learning...."

Though the foundation isn't prioritizing a particular issue, the application states that it is looking for ideas that have the potential to push the needle on one or more of the United Nations' 17 sustainable development goals, which include eliminating poverty and hunger as well as boosting climate action and protecting life on land and underwater.
The Foundation's most recent winner was Sweden-based Elypta, according to the article, "which Ipp said is using liquid biopsies, such as a blood test, to detect cancer early."

"We believe that building a better future requires a spirit of curiosity, a willingness to push boundaries, and the courage to think big," said Rod Roddenberry, co-founder of the Roddenberry Foundation. "The Prize will provide a significant boost to AI pioneers leading these efforts." According to the Foundation's announcement, the Prize "embodies the Roddenberry philosophy's promise of a future in which technology and human ingenuity enable everyone — regardless of background — to thrive."

"By empowering entrepreneurs to dream bigger and innovate valiantly, the Roddenberry Prize seeks to catalyze the development of AI solutions that promote abundance and well-being for all."

Researchers have devised a way to extract energy from the photosynthesis process of algae, according to an announcement from Concordia University.

Suspended in a specialized solution, the algae forms part of a "micro photosynthetic power cell" that can actually generate enough energy to power low-power devices like Internet of Things (IoT) sensors. "Photosynthesis produces oxygen and electrons. Our model traps the electrons, which allows us to generate electricity," [says Kirankumar Kuruvinashetti, PhD 20, now a Mitacs postdoctoral associate at the University of Calgary.] "So more than being a zero-emission technology, it's a negative carbon emission technology: it absorbs carbon dioxide from the atmosphere and gives you a current. Its only byproduct is water."

[...] Muthukumaran Packirisamy, professor in the Department of Mechanical, Industrial and Aerospace Engineering and the paper's corresponding author, admits the system is not yet able to compete in power generation with others like photovoltaic cells. The maximum possible terminal voltage of a single micro photosynthetic power cell is only 1.0V. But he believes that, with enough research and development, including artificial intelligence-assisted integration technologies, this technology has the potential to be a viable, affordable and clean power source in the future.

It also offers significant manufacturing advantages over other systems, he says. "Our system does not use any of the hazardous gases or microfibres needed for the silicon fabrication technology that photovoltaic cells rely on. Furthermore, disposing of silicon computer chips is not easy. We use biocompatible polymers, so the whole system is easily decomposable and very cheap to manufacture."
In the paper the researchers also described it as a âoemicrobial fuel cellâ...

Avian influenza outbreaks on US dairy farms have raised concerns about milk safety, leading some to consider alternatives like engineered milk proteins. Startups like Remilk and Alpine Bio are using yeast and soybeans to produce key milk proteins, aiming to replace dairy cows and reduce environmental impact. However, competing with subsidized dairy industries and their efficient use of cow byproducts remains a challenge for these biotech ventures, MIT Technology Review reports. The story adds: Everyone agrees that cow's milk will be difficult to displace. It holds a special place in the human psyche, and we owe civilization itself, in part, to domesticated animals. In fact, they've left their mark in our genes, with many of us carrying DNA mutations that make cow's milk easier to digest. But that's why it might be time for the next technological step, says Alpine's CEO Magi Richani. "We raise 60 billion animals for food every year, and that is insane. We took it too far, and we need options," she says. "We need options that are better for the environment, that overcome the use of antibiotics, and that overcome the disease risk." It's not clear yet whether the bird flu outbreak on dairy farms is a big danger to humans. But making milk without cows would definitely cut the risk that an animal virus will cause a new pandemic. As Richani says: "Soybeans don't transmit diseases to humans."

Due to complications with a mechanical heart pump, surgeons in New York removed a pig kidney from Lisa Pisano less than two months after transplanting it. The genetically engineered pig kidney did not show signs of rejection but suffered from inadequate blood flow. Wired reports: Pisano was facing heart and kidney failure and required routine dialysis. She wasn't eligible to receive a traditional heart and kidney transplant from a human donor because of several chronic medical conditions that reduced the likelihood of a good outcome. Pisano first received a heart pump at NYU Langone Health on April 4, followed by the pig kidney transplant on April 12. The heart pump, a device called a left ventricular assist device or LVAD, is used in patients who are either awaiting heart transplantation or otherwise aren't a candidate for a heart transplant.

In a statement provided to WIRED, Pisano's medical team explained that they electively removed the pig kidney on May 29-47 days after transplant -- after several episodes of the heart pump not being able to pass enough blood through the transplanted kidney. Steady blood flow is important so that the kidney can produce urine and filter waste. Without it, Pisano's kidney function began to decline. "On balance, the kidney was no longer contributing enough to justify continuing the immunosuppression regimen," said Robert Montgomery, director of the NYU Langone Transplant Institute, in the statement. Like traditional transplant patients, Pisano needed to take immunosuppressive drugs to prevent her immune system from rejecting the donor organ.

The kidney came from a pig genetically engineered by Virginia biotech company Revivicor to lack a gene responsible for the production of a sugar known as alpha-gal. In previous studies at NYU Langone, researchers found that removing this sugar prevented immediate rejection of the organ when transplanted into brain-dead patients. During Pisano's surgery, the donor pig's thymus gland, which is responsible for "educating" the immune system, was also transplanted to reduce the likelihood of rejection. A recent biopsy did not show signs of rejection, but Pisano's kidney was injured due to a lack of blood flow, according to the statement. The team plans to study the explanted pig kidney to learn more.

Gizmodo reports there's been progress on a male birth-control gel "being developed with the help of several organizations, including the U.S. government's National Institute of Child Health and Human Development, part of the larger NIH." It's now being tested in a larger-scale Phase IIB trial, which involves around 400 couples. [Five milliliters of gel — about a teaspon — is applied to each shoulder blade once a day, reports NBC News.] That trial is still ongoing, but researchers have already begun to pore through some of the available data, which has provided encouraging results. In the summer of 2022, for instance, Diana Blithe, chief of the NICHD's Contraceptive Development Program, reported that the NES/T gel's efficacy rate so far appeared to be on par or even better than contraceptive hormonal options for women...

The findings are still preliminary, and it will take more time for the full Phase II data to be collected and analyzed. But Blithe and her team have been encouraged by everything they've seen to date. In the team's early assessments, the gel appears to be both effective and safe, with minimal side effects for men taking it... Blithe and her colleagues are set to meet with the FDA next year about the steps needed to begin a larger Phase III trial and are still seeking a commercial partner to help bring the NES/T gel to the market.
Initial findings also showed that the contraceptive worked faster than expected, Blithe said, according to NBC News. They add that at least three other companies are also working on male birth control: Also at the Boston conference on Sunday, YourChoice Therapeutics said a very small trial in the U.K. — just 16 men — showed that its nonhormonal pill, YCT-529, was safe and free of side effects. The San Francisco company's nonhormonal pill works by blocking the vitamin A receptor important for male fertility.YourChoice is planning a larger trial, according to CEO Akash Bakshi.

"Chinese scientists develop cure for diabetes," reads the headline from the world's second-most widely read English-language newspaper. ("Insulin patient becomes medicine-free in just 3 months.")

The researchers' results were published earlier in May in Cell Discovery, and are now getting some serious scrutiny from the press. The Economic Times cites a University of British Columbia professor's assessment that the study "represents an important advance in the field of cell therapy for diabetes," in an article calling it a "breakthrough" that "marks a significant advancement in cell therapy for diabetes." Chinese scientists have successfully cured a patient's diabetes using a groundbreaking cell therapy... According to a South China Morning Post report, the patient underwent the cell transplant in July 2021. Remarkably, within eleven weeks, he no longer required external insulin. Over the next year, he gradually reduced and ultimately stopped taking oral medication for blood sugar control. "Follow-up examinations showed that the patient's pancreatic islet function was effectively restored," said Yin, one of the lead researchers. The patient has now been insulin-free for 33 months... The new therapy involves programming the patient's peripheral blood mononuclear cells, transforming them into "seed cells" to recreate pancreatic islet tissue in an artificial environment.
Their article calls it "a significant medical milestone" — noting that 140 million people in China have diabetes (according to figures from the International Diabetes Federation).

Thanks to long-time Slashdot reader AmiMoJo for sharing the news.

"A Swiss biocomputing startup has launched an online platform that provides remote access to 16 human brain organoids," reports Tom's Hardware: FinalSpark claims its Neuroplatform is the world's first online platform delivering access to biological neurons in vitro. Moreover, bioprocessors like this "consume a million times less power than traditional digital processors," the company says. FinalSpark says its Neuroplatform is capable of learning and processing information, and due to its low power consumption, it could reduce the environmental impacts of computing. In a recent research paper about its developments, FinalSpakr claims that training a single LLM like GPT-3 required approximately 10GWh — about 6,000 times greater energy consumption than the average European citizen uses in a whole year. Such energy expenditure could be massively cut following the successful deployment of bioprocessors.

The operation of the Neuroplatform currently relies on an architecture that can be classified as wetware: the mixing of hardware, software, and biology. The main innovation delivered by the Neuroplatform is through the use of four Multi-Electrode Arrays (MEAs) housing the living tissue — organoids, which are 3D cell masses of brain tissue...interfaced by eight electrodes used for both stimulation and recording... FinalSpark has given access to its remote computing platform to nine institutions to help spur bioprocessing research and development. With such institutions' collaboration, it hopes to create the world's first living processor.
FinalSpark was founded in 2014, according to Wikipedia's page on wetware computing. "While a wetware computer is still largely conceptual, there has been limited success with construction and prototyping, which has acted as a proof of the concept's realistic application to computing in the future."

Thanks to long-time Slashdot reader Artem S. Tashkinov for sharing the article.

An anonymous reader quotes a report from The Guardian: Proteins in the blood could warn people of cancer more than seven years before it is diagnosed, according to research [published in the journal Nature Communications]. Scientists at the University of Oxford studied blood samples from more than 44,000 people in the UK Biobank, including over 4,900 people who subsequently had a cancer diagnosis. They compared the proteins of people who did and did not go on to be diagnosed with cancer and identified 618 proteins linked to 19 types of cancer, including colon, lung, non-Hodgkin lymphoma and liver.

The study, funded by Cancer Research UK and published in Nature Communications, also found 107 proteins associated with cancers diagnosed more than seven years after the patient's blood sample was collected and 182 proteins that were strongly associated with a cancer diagnosis within three years. The authors concluded that some of these proteins could be used to detect cancer much earlier and potentially provide new treatment options, though further research was needed.

Brian Shelton's type 1 diabetes was treated with an infusion of insulin-producing pancreas cells (grown from stem cells). In 2021, the New York Times reported: Now his body automatically controls its insulin and blood sugar levels. Shelton, now 64, may be the first person cured of the disease with a new treatment that has experts daring to hope that help may be coming for many of the 1.5 million Americans suffering from Type 1 diabetes. "It's a whole new life," Shelton said. Diabetes experts were astonished but urged caution. The study is continuing and will take five years, involving 17 people with Type 1 diabetes.
"By fall 2023, three patients, including Shelton, had achieved insulin independence by day 180 post-transplant," MedScape reported (in January of 2024): In the phase 1/2 study, 14 patients with type 1 diabetes and impaired hypoglycemia awareness or recurrent hypoglycemia received portal vein infusions of VX-880 [Vertex Pharmaceutical's pancreatic islet cell replacement therapy] along with standard immunosuppression. As of the last data cut, all 14 patients demonstrated islet cell engraftment and production of endogenous insulin. After more than 90 days of follow-up, 13 of the patients have achieved A1c levels < 7% without using exogenous insulin.
Brian Shelton and another patient died, and while Vertex says their deaths were unrelated to the treatment, they have "placed the study on a protocol-specified pause, pending review of the totality of the data by the independent data monitoring committee and global regulators." (MedScape adds that Vertex "is continuing with a phase 1/2 clinical trial of a different product, VX-264, which encapsulates the same VX-880 cells in a device designed to eliminate the need for immunosuppression.")

And meanwhile, a new study in China (again using stem cell-derived islet tissue) has provided "encouraging evidence that islet tissue replacement is an effective cure for diabetic patients," the researchers wrote in Nature. The treatment was administered to 59-year-old, type-2 diabetic.

"Marked changes in the patient's glycemic control were observed as early as week 2," the researchers write, and after week 32, the patient's Time In Tight Range (TITR) "had readily reached 99% and was maintained thereafter."

Thanks to long-time Slashdot reader hackingbear for sharing the news.